Strategic Partnerships Simcere is actively expanding via strategic collaborations with Reyoung Bio and Roche, signaling a receptiveness to co-development, licensing, and commercialization partnerships that can open new markets and accelerate product pipelines.

Infectious Disease Focus With an established infectious disease portfolio and recent collaboration for Clulevibart Injection, pursue opportunities to supply biologics, vaccines, or adjunct therapies to bolster Simcere's infectious disease offerings and capitalize on market demand.

T Cell Engineered Simcere Zaiming is developing T-cell engager platforms, presenting a pathway for high-value biologics partnerships, licensing of novel formats, and potential co-development of next‑gen immuno-oncology programs.

Revenue Momentum H1 2026 revenue reached RMB 4,580m with a 27.8% YoY rise; strong topline growth and sizable six-month revenue indicate capability and appetite for scaled commercial execution across multiple markets.

Global Licensing Current licensing with Roche for SIM0660 and a global reach strategy creates a template for further international licenses and strategic distribution deals to extend product reach and diversify revenue streams.